The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review
- 323 Downloads
Purpose of Review
Nutraceuticals are a form of complementary and alternative medicine that is commonly used by children and adolescents with migraine. In this review, observational studies, randomized controlled trials, systematic reviews, and meta-analyses on the efficacy and safety of single compound nutraceuticals for the management of migraine in children and adolescents were identified through a literature search of MEDLINE, Embase, and EBM Reviews—Cochrane Central Register of Controlled Trials.
Twenty-one studies were reviewed, of which 11 were observational studies, 7 were randomized controlled trials, and 3 were systematic reviews. Six different nutraceuticals were included in the review: vitamin D, riboflavin, coenzyme Q10, magnesium, butterbur, and polyunsaturated fatty acids. All but three of the studies assessed the role of nutraceuticals in migraine prevention, while three studies evaluated the role of intravenous magnesium for acute migraine management. Overall, the quality and size of the studies were limited.
Due to low quality evidence and limited studies, no definite conclusions can be drawn on the efficacy of nutraceuticals for the treatment of pediatric migraine. Future studies are warranted in order to establish evidence upon which to define the role of nutraceuticals in this patient population.
KeywordsPediatric migraine Nutraceuticals Vitamins Prophylaxis Prevention Acute treatment
Compliance with Ethical Standards
Conflict of Interest
Serena L. Orr declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Shamliyan T, Kane R, Ramakrishnan R, Taylor F. Migraine in children: preventive pharmacologic treatments. Rockv Agency Healthc Res Qual. 2013;28(108):1225–37.Google Scholar
- 6.•• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24. The CHAMP study is the highest quality pediatric migraine prevention trial to date. CrossRefPubMedGoogle Scholar
- 7.Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL. Childhood and adolescent migraine prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53(5):799–816.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Kalra EK. Nutraceutical-definition and introduction. AAPS PharmSciTech. 2003;5(3):E25.Google Scholar
- 12.• Groenewald CB, Beals-Erickson SE, Ralston-Wilson J, Rabbitts JA, Palermo TM. Complementary and alternative medicine use by children with pain in the United States. Acad Ped. 2017;17(7):785–93. This study highlights the prevalence of complementary and alternative medicine use amongst children and adholescents with headache and other pain conditions. CrossRefGoogle Scholar
- 28.Markley H. Prophylactic treatment of headaches in adolescents with riboflavin. Cephalalgia. 2009;29(S1):100.Google Scholar
- 32.• Namazi N, Heshmati J, Tarighat-Esfanjani A. Supplementation with riboflavin (vitamin B2) for migraine prophylaxis in adults and children: a review. Int J Vitam Nutr Res. 2015;85(1–2):79–87. This systematic review addresses the conclusions that can be drawn from the available data on riboflavin for migraine treatment. CrossRefPubMedGoogle Scholar
- 34.Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: effects on clinical features and inflammatory markers. Nutr Neurosci. 2018 1–9.Google Scholar
- 35.•• Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32. This is one of the two initial published randomized controlled trials assessing the efficacy and safety of CGRP receptor antagonists for migraine prevention in adults. CrossRefPubMedGoogle Scholar
- 36.•• Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. This is one of the two initial published randomized controlled trials assessing the efficacy and safety of CGRP receptor antagonists for migraine prevention in adults. CrossRefPubMedGoogle Scholar
- 43.Martinez Cardenas V, Rodriguez M, Burke M, Vasconcellos E. Efficacy and safety of intravenous magnesium sulfate treatment in pediatric patients with headaches. Headache. 2012;52(5):896.Google Scholar
- 44.Gertsch EA, Loharuka S, Wolter-Warmerdam KG, Tong S, Kedia S. Intravenous magnesium as abortive treatment for headaches in children. Ann Neurol. 2011;Conference(var.pagings):S167.Google Scholar
- 50.Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–53.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie S, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(S2):1–62.Google Scholar
- 54.Mauskop A. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80(9):868–9.CrossRefPubMedGoogle Scholar
- 55.Fiebich B, Grozdeva M, Hess S, Hüll M, Danesch U, Bodensieck A, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 2005;71(1):12–9.CrossRefPubMedGoogle Scholar
- 57.Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45(3):196–203.Google Scholar
- 59.Avula B, Wang Y-H, Wang M, Smillie TJ, Khan IA. Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids from the rhizomes of Petasites hybridus (L.) G.M. et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS methods. J Pharm Biomed Anal. 2012;70:53–63.CrossRefPubMedGoogle Scholar
- 61.Prieto JM. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Bot Targets Ther. 2014;4:1–9.Google Scholar
- 65.Fayyazi A, Khajeh A, Ghazavi A, Sangestani M. Omega 3 in childhood migraines: a double blind randomized clinical trial. Iran J Child Neurol. 2016;10(1):14–21.Google Scholar
- 66.•• Le K, Yu D, Wang J, Ali AI, Guo Y. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain. 2017;18(1):69. This is a systematic review and meta-analysis that pooled all of the evidence for topiramate in pediatric migraine prevention. CrossRefPubMedPubMedCentralGoogle Scholar